Gyre TherapeuticsGYRE +1.29%39 Gross Margin % is 94.55% as of Mar. 2026, which is 1% below its 10-year median of 95.51. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 737 Biotechnology companies, Gyre Therapeutics ranks better than 93.22% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Gyre Therapeutics had a gross margin of 94.55% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Gyre Therapeutics Gross Margin % Related Terms
Gyre Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GYRE vs CBIO, RIGL, ARVN: Gross Margin % Comparison
For the Biotechnology subindustry, Gyre Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Gyre Therapeutics (GYRE) has a Gross Margin % of 94.55% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Gyre Therapeutics and its competitors. This is near median its historical median of 95.51. Over the past decade, Gyre Therapeutics' Gross Margin % has ranged from 95.09 to 96.33. According to the industry distribution chart, Gyre Therapeutics ranks #50 out of 737 companies in the Biotechnology industry, placing it in the top 6.8%.
Is Gyre Therapeutics' Gross Margin % too high?
Gyre Therapeutics' current Gross Margin % of 94.55% is near median its 10-year median of 95.51. Over the past 10 years, this metric has ranged from a low of 95.09 to a high of 96.33. The Biotechnology industry median Gross Margin % is 60.92. Gyre Therapeutics' value of 94.55% is 55.2% above this industry median. Based on the distribution chart, Gyre Therapeutics ranks #50 out of 737 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Gross Margin % compare to CBIO and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #50 out of 737 companies for Gross Margin %. This places Gyre Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.92. Gyre Therapeutics' value of 94.55% is 55.2% above this benchmark. Historically, Gyre Therapeutics' own Gross Margin % has ranged from 95.09 to 96.33 over the past decade. While the company's 10-year median is 95.51 vs. the industry median of 60.92, Gyre Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Gross Margin % of 94.55% is 55.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Gross Margin % is 94.55%, which is near median its own 10-year median of 95.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current Gross Margin % is 94.55%, which is near median its 10-year median of 95.51 and 55.2% above the Biotechnology industry median of 60.92. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Gross Margin % is 94.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
Gross Margin %: 94.55% (near median its 10-year median of 95.51)
GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
Industry Position: 55.2% above the Biotechnology median (#50 of 737)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
